Systemic Mastocytosis (DBCOND0028386)
Identifiers
- Synonyms
- Mastocytosis, Systemic / Systemic mastocytosis / Systemic mastocytosis (morphologic abnormality) / Malignant systemic mastocytosis (morphologic abnormality) / Systemic mast cell disease (disorder) / Isolated bone marrow mastocytosis (disorder) / Smoldering systemic mastocytosis (morphologic abnormality) / Smoldering systemic mastocytosis (disorder) / Indolent Systemic Mastocytosis / Indolent systemic mastocytosis (morphologic abnormality) / Indolent systemic mastocytosis (disorder)
Associated Data
- Indicated Drugs and Targets
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT06065007 Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis No drug interventions Not Available Not Available recruiting NCT05186753 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis treatment 2 recruiting NCT04681105 Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies treatment 1 active_not_recruiting NCT00109707 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies treatment 1 / 2 completed NCT00449748 Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis treatment 2 completed NCT00171912 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes treatment 2 completed NCT01297777 Imatinib in KIT-negative Systemic Mastocytosis treatment 4 completed NCT01807598 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia treatment 2 completed NCT03739606 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer treatment 2 withdrawn NCT01334996 Use of Tamoxifen in Systemic Mastocytosis No drug interventions Not Available Not Available completed NCT01602939 Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis treatment 2 / 3 unknown_status NCT02478957 Treatment of Indolent Systemic Mastocytosis With PA101 No drug interventions treatment 2 completed NCT03214666 GTB-3550 Tri-Specific Killer Engager (TriKEĀ®) for High Risk Hematological Malignancies treatment 1 / 2 terminated NCT02441166 Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis No drug interventions diagnostic Not Available completed NCT00918931 Obatoclax for Systemic Mastocytosis treatment 2 terminated NCT03401060 Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis treatment 3 completed NCT00979160 Evaluation of Response of Dasatinib to Treat Mastocytosis treatment 2 unknown_status NCT00493129 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) treatment 2 completed NCT02415608 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis treatment 2 terminated